B. Riley Securities Rates Unicycive Therapeutics (UNCY) buy

Analyst Mayank Mamtani has kept a buy rating on Unicycive Therapeutics, pointing to a $22 price target while the stock trades near $4.59, a 379.30% upside from the current price.

By TradeTexts Research Desk · Published Jun 30, 2026, 2:02 PM EDT · Updated Jul 1, 2026, 2:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

B. Riley Securities rated Unicycive Therapeutics, Inc. ($UNCY) "buy" with a $22 price target on June 30, 2026.

Since the rating, $UNCY is up 15.8% after 1 week, up 13.0% after 1 month and down 28.4% to date (from the $4.69 close on Jun 30, 2026).

UNCY Unicycive Therapeutics, Inc.

$3.36 -42.07% year to date

Daily close · Oct 16, 2026

Key Points

B. Riley Securities reiterated its buy rating on Unicycive Therapeutics, Inc. (NasdaqCM: UNCY) with a price target of $22 on June 30, 2026.
B. Riley Securities's $22 price target implies 379.30% upside from Unicycive Therapeutics, Inc.'s ($UNCY) current $4.59 share price.
Unicycive stock changed hands at $4.59, sitting below its 50-day moving average of $5.22 and its 52-week high of $8.74.
Across ten analyst opinions, the company carries a consensus target mean price of $29.60, with targets ranging from $15.00 to $50.00.

Get $UNCY trade alerts by text

We text you when insiders, Congress or big funds trade $UNCY. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Unicycive Therapeutics, Inc. alert may contain errors. Disclosures

B. Riley Reaffirms Unicycive Target

B. Riley Securities analyst Mayank Mamtani reiterated a buy rating on Unicycive Therapeutics, Inc. (NasdaqCM: UNCY) on June 30, 2026, keeping a price target of $22.00 on the shares. The update calls attention to a wide gap between the firm's target and the company's current market price, focusing attention on how upside expectations stack up against recent trading levels in the biotech sector.

Analyst rating track record

B. Riley Securities vs. the S&P 500

YTD return +15.54% hypothetical

All-time return +59.44% S&P 500 +20%

vs. S&P 500 +39.44% ahead of the index

Hypothetical returns from B. Riley Securities's disclosed trades, not real profit or advice. How we model this.

Stock Price and Trading Range

Unicycive shares traded at $4.59, lingering near the lower end of their 52-week range of $3.71 to $8.74. The stock remains below both its 50-day moving average of $5.22 and its 200-day moving average of $6.38. With a market capitalization of $132.87 million and a forward P/E ratio of 2.87, the clinical-stage company continues to see heavy attention from covering institutions despite its volatile trading path.

12-month forecast

$UNCY price target

Unicycive Therapeutics, Inc. daily closes and this analyst's $22 target. Not advice.

Recent Analyst Updates

Wall Street firms have kept a steady stream of updates on the biotechnology developer over the summer months. On June 30, 2026, HC Wainwright & Co. maintained a buy rating while adjusting its target to $15.00 from $22.00, matching B. Riley's action on the same date. Later in the summer, Benchmark maintained a speculative buy rating with a $13.00 target on August 20, 2026, following an earlier $15.00 target on August 20 and a $13.00 target on July 1, 2026. Guggenheim also maintained a buy rating with a $25.00 target on August 13, 2026, lowering it from $37.00. Noble Capital Markets previously kept an outperform rating with a $50.00 target on July 1, 2026. Across ten analyst opinions, Unicycive holds a consensus target mean price of $29.60, with projections spanning from a low of $15.00 up to a high of $50.00.

What Unicycive Therapeutics Does

Unicycive Therapeutics is a clinical-stage biotechnology company based in Mountain View, California, focused on developing treatments for kidney diseases. Its pipeline features oxylanthanum carbonate, a lanthanum-based phosphate binding agent for hyperphosphatemia in chronic kidney disease patients on dialysis, alongside UNI-494 for acute and chronic kidney injury. The firm employs 21 people and was incorporated in 2016.

What's Ahead for UNCY

Investors are keeping an eye on upcoming pipeline milestones and financial updates, with the company's next earnings report expected around November 12, 2026. Coverage from firms like B. Riley and HC Wainwright highlights ongoing interest in the company's clinical programs as management works toward commercializing its lead kidney disease therapies.